课题基金 / 基金详情

African-Americans with Atopic Dermatitis: Skin Barrier and Immune

African-Americans with Atopic Dermatitis: Skin Barrier and Immune
患有特应性皮炎的非裔美国人:皮肤屏障和免疫
批准号:
9868281
负责人:
David Margolis
金额:
$34.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-02-18 至 2021-11-30

项目摘要

项目成果

David Margolis的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Atopic dermatitis (AD) is a highly pruritic chronic episodic inflammatory skin disease that often presents between 3 and 6 months of age but may also present during later childhood or in adulthood. In the US, AD affects roughly 10-20% of all children of all races and ethnic groups. The highest prevalence of AD in the US is among African-Americans. The prevalence of AD is increasing worldwide and it is a major public health burden. The majority of children with AD will also develop asthma and seasonal allergies. From the recent Global Burden of Disease study, AD was among the top 50 most prevalent diseases worldwide and it had the second highest disability rank of all non-malignant skin diseases. Recent studies have established a strong association between loss-of-function mutations in filaggrin (FLG), a gene coding for a protein responsible for maintaining an intact skin barrier and AD. We have already demonstrated that these mutations are also associated with more persistent AD. However, these mutations are rarely noted in children of African ancestry. As a result, there is a gap in our knowledge with respect to the basic biology of AD in African-Americans. We recently found that mutations in filaggrin-2 (FLG2) are associated with persistence of AD in African-American children. We have also shown that genetic variation of the gene that codes thymic stromal lymphopoietin appears to modify the association of FLG with AD. The goals of this proposal are to comprehensively explore the association of FLG2 with AD in African-Americans, to better understand the association of thymic stromal lymphopoietin with the persistence of AD, and to explore how TSLP/FLG2 interact to create the phenotype of persistent AD. We will continue to focus on loss-of- function mutations in skin barrier genes using FLG as a model, a concept that was recently justified by a report that LOF may be a preferred pathway for adaptation to environmental stimuli. We plan to focus our studies on African-Americans. This proposal has two goals. The first goal is to better understand FLG2 loss-of-function mutations in African Americans. The second goal is to better understand TSLP variation and ultimately the interaction between TSLP and barrier dysfunction.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
Identification of HLA-DPA1*01:03:01:57 and HLA-DPA1*02:01:01:29 from a case-control study of atopic dermatitis.
从特应性皮炎病例对照研究中鉴定 HLA-DPA1*01:03:01:57 和 HLA-DPA1*02:01:01:29。
DOI: 10.1111/tan.14900
发表时间: 2023
期刊: HLA
影响因子: 8
作者: [Damianos,Georgios, Duke,JamieL, Pagkrati,Ioanna, Margolis,DavidJ, Monos,DimitriS]
通讯作者: Monos,DimitriS
DOI: 10.1007/s00403-021-02319-7
发表时间: 2022-12
期刊: Archives of dermatological research
影响因子: 3
作者: []
通讯作者:
DOI: 10.1016/j.humimm.2021.04.001
发表时间: 2021-08
期刊: Human immunology
影响因子: 2.7
作者: [Margolis DJ, Mitra N, Duke JL, Berna R, Margolis JD, Hoffstad O, Kim BS, Yan AC, Zaenglein AL, Chiesa Fuxench Z, Dinou A, Wasserman J, Tairis N, Mosbruger TL, Ferriola D, Damianos G, Kotsopoulou I, Monos DS]
通讯作者: Monos DS
DOI: 10.4049/jimmunol.2001252
发表时间: 2021-05-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Margolis DJ, Mitra N, Kim BS, Duke JL, Berna RA, Hoffstad OJ, Wasserman JR, Ferriola DA, Mosbruger TL, Wubbenhorst BS, Nathanson KL, Monos DS]
通讯作者: Monos DS
A randomized, double-blind, multi-center comparative effectiveness study of spironolactone versus doxycycline hyclate for the treatment of acne in women
  • 批准号:
    10296086
  • 项目类别:
  • 资助金额:
    $104.05万
  • 财政年份:
    2021
  • 负责人:
    David Margolis
  • 依托单位:
A randomized, double-blind, multi-center comparative effectiveness study of spironolactone versus doxycycline hyclate for the treatment of acne in women
  • 批准号:
    10470869
  • 项目类别:
  • 资助金额:
    $102.93万
  • 财政年份:
    2021
  • 负责人:
    David Margolis
  • 依托单位:
Comparative effectiveness of spironolactone versus oral tetracycline-class antibiotics for the treatment of moderate to severe acne in women
  • 批准号:
    9815052
  • 项目类别:
  • 资助金额:
    $24.95万
  • 财政年份:
    2019
  • 负责人:
    David Margolis
  • 依托单位:
NOS1AP and Capon Associated Impaired Healing in Those with Diabetic Foot Ulcers
  • 批准号:
    9925084
  • 项目类别:
  • 资助金额:
    $60.51万
  • 财政年份:
    2018
  • 负责人:
    David Margolis
  • 依托单位:
海外基金